C4 Therapeutics, Inc. — Director's Dealing 2021

Dec 17, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: C4 Therapeutics, Inc. (CCCC)
CIK: 0001662579
Period of Report: 2021-12-17

Reporting Person: Salter Malcolm (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-12-17	Common Stock	S	755	$30.25	Disposed	10952	Direct

Footnotes

F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on April 15, 2021.